HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Celularity Inc.

Contributing Author

Recent Articles by Celularity Inc.

Oct-30
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care CELU GlobeNewswire
Oct-14
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease CELU GlobeNewswire
Sep-03
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance CELU GlobeNewswire
Aug-22
Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU GlobeNewswire
Aug-18
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt CELU GlobeNewswire
Jul-09
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law CELU GlobeNewswire
Jul-01
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies CELU GlobeNewswire
Jun-10
Celularity Announces Chief Financial Officer Transition CELU GlobeNewswire
Jun-02
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology CELU GlobeNewswire
May-30
Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU GlobeNewswire
May-09
Celularity Announces Full Year 2024 Operating and Financial Results CELU GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite